Medical specialists from Finland tagged as investigators in clinical trials studying Leukemia, Myeloid

Total 26 results

Anna-Leena Huusko
Seen in:
- Oulu, Oulu University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Annasofia Holopainen
Seen in:
- Kuopio, Kuopio University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Antti Turunen
Seen in:
- Kuopio, Kuopio University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Anu Partanen
Seen in:
- Kuopio, Kuopio University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Jenni Pylkäs
Seen in:
- Oulu, Oulu University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Johanna Rimpiläinen
Seen in:
- Tampere, FI-Tampere-TAYS
- Tampere, Tampere University Hospital
Trials:
- NCT04027309 (Principal Investigator)
- NCT05428969 (Principal Investigator)
Conditions:
Jokke Hannuksela
Seen in:
- Oulu, Oulu University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Kimmo Porkka
Seen in:
- Helsinki, Helsinki University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Kirsi Launonen
Seen in:
- Oulu, Oulu University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Maija Itälä-Remes, Prof. Dr.
Seen in:
- Turku, Turku University Central Hospital
Trials:
- NCT04232241 (Principal Investigator)
Conditions:
Manna Miilunpohja
Seen in:
- Kuopio, Kuopio University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Marja Pyörälä
Seen in:
- Kuopio, Kuopio University Hospital
Trials:
- NCT05428969 (Principal Investigator)
Conditions:
Marjaana Säily
Seen in:
- Oulu, Oulu University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Mika Kontro
Seen in:
- Helsinki, FI-Helsinki-HUS
- Helsinki, Helsinki University Hospital
Trials:
- NCT04027309 (Principal Investigator)
- NCT05428969 (Principal Investigator)
Conditions:
Mikko Myllymäki
Seen in:
- Helsinki, Helsinki University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Milla Kuusisto
Seen in:
- Oulu, Oulu University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Perttu Koskenvesa
Seen in:
- Helsinki, Helsinki University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Riikka Räty
Seen in:
- Helsinki, Helsinki University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Sakari Kakko
Seen in:
- Oulu, Oulu University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Samppa Ryhänen, MD, PhD
Seen in:
- Helsinki, Division of Hematology, Oncology, and Stem Cell Transplantation, The New Children's Hospital, Helsinki University Hospital
Trials:
- NCT05477589 (Principal Investigator)
Conditions:
- Stem Cell Transplantation;
- Acute Myeloid Leukemia (AML) in Remission
Sari Kytölä
Seen in:
- Helsinki, Helsinki University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Sari Luopajärvi
Seen in:
- Tampere, Tampere University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Sirpa Koskela
Seen in:
- Tampere, Tampere University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Taru Kuittinen
Seen in:
- Kuopio, Kuopio University Hospital
Trials:
- NCT05428969 (Sub-Investigator)
Conditions:
Timo Siitonen
Seen in:
- Oulu, Oulu University Hospital
Trials:
- NCT05428969 (Principal Investigator)
Conditions:
Urpu Salmenniemi, Prof. Dr.
Seen in:
- Turku, Turku University Central Hospital
Trials:
- NCT04232241 (Sub-Investigator)
Conditions:

Clinical Trials on Leukemia, Myeloid

University of Pennsylvania

Active, not recruiting

CD123 Redirected T Cells for AML in Pediatric Subjects

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, Pediatric

United States
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Leukemia

China
Washington University School of Medicine

Withdrawn

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia

United States
C. Babis Andreadis
Gateway for Cancer Research; AVEO Pharmaceuticals, Inc.

Terminated

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia

United States
Xuzhou Medical University

Recruiting

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Peking University People's Hospital
Beijing JD Biotech Co. LTD.

Recruiting

Off-the-shelf CD123 CAR-NK for R/R AML

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Xuzhou Medical University

Recruiting

Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Bio-Path Holdings, Inc.

Recruiting

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Beijing Boren Hospital

Recruiting

Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse Leukemia

China
Yale University
Pfizer

Terminated

GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia

ACUTE MYELOID LEUKEMIA

United States

Medical specialists from Finland tagged as investigators in clinical trials studying Leukemia, Myeloid

Clinical Trials on Leukemia, Myeloid

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations